TY  - GEN
AU  - Zheng,Hanrui
AU  - Qin,Zhou
AU  - Qiu,Xingjian
AU  - Zhan,Mei
AU  - Wen,Feng
AU  - Xu,Ting
TI  - Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml
SN  - 1941-837X
PY  - 2021///0121
KW  - Antibodies, Monoclonal, Humanized
KW  - economics
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Carcinoma, Hepatocellular
KW  - drug therapy
KW  - Cost-Benefit Analysis
KW  - Disease-Free Survival
KW  - Humans
KW  - Liver Neoplasms
KW  - Markov Chains
KW  - Sorafenib
KW  - Treatment Outcome
KW  - United States
KW  - alpha-Fetoproteins
KW  - administration & dosage
KW  - Ramucirumab
N1  - Publication Type: Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1080/13696998.2019.1707211
ER  -